Biotricity Q3 2024 Adj EPS $(0.12) Beats $(0.44) Estimate, Sales $2.97M Miss $3.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biotricity (NASDAQ:BTCY) reported Q3 2024 adjusted EPS of $(0.12), surpassing the $(0.44) estimate, but its sales of $2.97M fell short of the $3.00M estimate. This represents a 20.90% increase in sales compared to the same period last year.
February 20, 2024 | 11:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biotricity reported a smaller than expected Q3 2024 loss per share but missed sales estimates slightly, showing a significant year-over-year sales increase.
Beating the EPS estimate significantly while missing the sales estimate marginally suggests a positive outlook on cost management and potential for profitability, which could positively impact investor sentiment. The year-over-year sales growth further supports a positive trajectory for the company.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100